Unit of Urology, Department of Urology, San Raffaele Scientific Institute, IRCCS Ospedale San Raffaele, Via Olgettina 60, 20132, Milan, Italy.
Division of Experimental Oncology, Urological Research Institute (URI), IRCCS Ospedale San Raffaele, Milan, Italy.
World J Urol. 2021 Aug;39(8):2961-2968. doi: 10.1007/s00345-020-03572-7. Epub 2021 Jan 1.
The role of non-tumour renal biopsy in predicting renal function after surgery for renal cell carcinoma (RCC) is poorly investigated. The aim of the study was to assess the impact of renal parenchymal histology on renal function after radical nephrectomy in a cohort of patients with RCC.
This cohort study included 171 patients with RCC submitted to radical nephrectomy between 2006 and 2018. Two biopsy samples from normal parenchyma were collected at nephrectomy and renal parenchyma damage (RPD) was scored on histologic samples according to validated methodology. The outcomes were eGFR after surgery and its reduction > 25% relative to baseline at maximum 12 months' follow-up. Linear and logistic multivariable regression were used, adjusting for age at surgery, presence of hypertension, diabetes, clinical tumour size, time from surgery and basal eGFR.
171 patients were enrolled and RPD was demonstrated in 64 (37%). Patients with RPD had more comorbidities (CCI > 2 in 25 vs. 9%, p < 0.001), in particular hypertension (70 vs. 53%; p = 0.03), diabetes with (5% vs. 0%, p = 0.007) or without (31 vs. 18%; p = 0.007) organ damage, cerebrovascular disease (19 vs. 5%; p = 0.006) and nephropathy (20 vs. 3%; p = 0.0004). At multivariable analyses, RPD was associated with lower eGFR (Est. - 5.48; 95% CI - 9.27: - 1.7; p = 0.005) and with clinically significant reduction of eGFR after surgery (OR 3.06; 95% CI 1.17: 8.49; p = 0.026).
Presence of RPD in non-tumour renal tissue is an independent predictor of functional impairment in patients with RCC. Such preliminary finding supports the use of parenchyma biopsy during clinical decision making.
非肿瘤肾活检在预测肾细胞癌(RCC)手术后肾功能的作用尚未得到充分研究。本研究的目的是评估肾实质组织学对 RCC 患者根治性肾切除术后肾功能的影响。
本队列研究纳入了 2006 年至 2018 年间接受根治性肾切除术的 171 例 RCC 患者。在肾切除术中采集了 2 份正常肾组织的活检样本,并根据已验证的方法对组织学样本进行了肾实质损伤(RPD)评分。主要结局为术后 eGFR 及其与基线相比在 12 个月随访时下降>25%。采用线性和逻辑多变量回归,调整手术时的年龄、高血压、糖尿病、临床肿瘤大小、手术时间和基础 eGFR。
共纳入 171 例患者,其中 64 例(37%)存在 RPD。存在 RPD 的患者合并症更多(CCI>2 为 25%,而 9%,p<0.001),尤其是高血压(70%,而 53%;p<0.001)、糖尿病伴(5%,而 0%;p<0.007)或不伴(31%,而 18%;p<0.007)器官损伤、脑血管疾病(19%,而 5%;p<0.006)和肾病(20%,而 3%;p=0.0004)。多变量分析显示,RPD 与 eGFR 降低相关(估计值为-5.48;95%CI-9.27:-1.7;p=0.005),且与术后 eGFR 显著下降相关(OR 3.06;95%CI 1.17:8.49;p=0.026)。
非肿瘤肾组织中存在 RPD 是 RCC 患者肾功能损害的独立预测因素。这些初步发现支持在临床决策中使用肾组织活检。